Description
(AWP Alliance News) - Lonza signed an agreement to acquire five US contract development and manufacturing sites from Merck at an enterprise valuation in the low- to mid-triple-digit millions of Swiss francs. The acquisition will expand its US network from four to nine sites, adding capabilities in bioconjugates, viral vectors and advanced drug delivery.
Approximately 1,100 employees will transfer, bringing its US workforce to more than 6,000. The cash transaction will be funded through available cash and existing credit facilities, with closing expected in mid-2027 subject to customary conditions. The acquired sites are expected to generate around CHF 250 million in sales in 2028 at a core EBITDA margin below Lonza's.
https://www.publicnow.com/view/E4E5A1B935F0FE81932035A06C5B0618FC6A794E…
Disclaimer: This news brief was created using generative artificial intelligence. Lonza Group Ltd. published the original content used to generate this news brief via EQS News on November 03, 2026, and is solely responsible for the information contained therein.
